Skip to main content
. 2019 Mar 21;4(6):e126543. doi: 10.1172/jci.insight.126543

Figure 6. miR-155 positively correlates with immune infiltration in human solid tumors.

Figure 6

(A) Mature miR-155 transcript reads per million in the log scale were plotted across TCGA cohorts. (B) Summary of differential upregulation of immune-associated genes in miR-155–high tumor subsets. The frequency at which the genes were found to be upregulated across TCGA tumors is plotted. (C) Summary of top GSEA results from miR-155–high subsets of TCGA tumors. Color scale indicates the cumulative normalized enrichment score (NES) across 30 TCGA cohorts. (D) PCA of immune-associated gene expression using miR-155–high versus miR-155–low subsets of TCGA tumors. Data from 30 different TCGA cohorts were aggregated, resulting in 6,414 patients (3,201 belonging to miR-155–high subset and 3,213 belonging to miR-155–low subset). A total of 2,038 genes with human “immune process” GO annotation were used for this analysis. Separation of red and blue points indicates that miR-155–high tumors have a shared immune-related gene expression profile that is distinct from miR-155–low tumors across TCGA data sets. (E) PCA of TCGA tumor samples by using all shared genes in RNAseq data sets (15,151 genes analyzed). (F) Scatter plot showing an inverse correlation between the univariate Cox proportional hazard ratio (HR) of miR-155 and the average levels of miR-155 expression in TCGA tumors. Dashed line denotes HR of 1, which indicates no effect on survival. Red color gradient indicates the median genomic mutational burden in these tumors. High mutational burden was found to be loosely associated with a lower HR (i.e., improved clinical outcome). BLCA, bladder urothelial carcinoma; LGG, brain lower grade glioma; BRCA, breast invasive carcinoma; CESC, cervical squamous cell carcinoma and endocervical adenocarcinoma; COAD, colon adenocarcinoma; ESCA, esophageal carcinoma; HNSC, head and neck squamous cell carcinoma; KIRC, kidney renal clear cell carcinoma; KIRP, kidney renal papillary cell carcinoma; LIHC, liver hepatocellular carcinoma; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; OV, ovarian serous cystadenocarcinoma; PAAD, pancreatic adenocarcinoma; READ, rectal adenocarcinoma; SARC, sarcoma; SKCM, skin cutaneous melanoma; STAD, stomach adenocarcinoma; UCEC, uterine corpus endometrial carcinoma.